Literature DB >> 7714788

Intravenous caffeine in stimulant drug abusers: subjective reports and physiological effects.

C R Rush1, J T Sullivan, R R Griffiths.   

Abstract

The present study was conducted to examine the self-reported (i.e., subjective) and physiological effects of intravenous caffeine in 10 subjects with histories of stimulant drug abuse. Under double-blind conditions, subjects received each dose of caffeine (0, 37.5, 75, 150 or 300 mg/70 kg) twice according to a latin-square design; injections were 10 sec in duration and separated by at least 24 hr. Effects were measured before injection and repeatedly afterward for 60 min. Caffeine dose-dependently increased ratings of positive mood (e.g., increased ratings of drug liking and high), which peaked at 2 min after injection and progressively decreased. Caffeine also dose-dependently increased the frequency of stimulant identifications on the Pharmacological Class Identification Questionnaire (e.g., like cocaine, amphetamine). Caffeine also produced negative-mood effects (e.g., increased ratings of bad effects) and increases in self-reported desire for cocaine. In contrast to the positive-mood effects, the negative-mood effects were of smaller magnitude and only significant at the highest dose. Caffeine increased reports of unusual smells and tastes. Caffeine decreased heart rate (7 bpm) and skin temperature (4 degrees C), and increased systolic and diastolic blood pressures (8 and 6 mm Hg, respectively). The mood effects but not the physiological effects of intravenous caffeine were similar to those previously observed with cocaine in studies using similar methods and subjects. Intravenous caffeine administration may provide a useful model system for investigating factors relevant to the use and abuse of stimulant drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714788

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Caffeine, a common active adulterant of cocaine, enhances the reinforcing effect of cocaine and its motivational value.

Authors:  José Pedro Prieto; Cecilia Scorza; Gian Pietro Serra; Valentina Perra; Martín Galvalisi; Juan Andrés Abin-Carriquiry; Giovanna Piras; Valentina Valentini
Journal:  Psychopharmacology (Berl)       Date:  2016-06-07       Impact factor: 4.530

2.  Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine.

Authors:  Matthew W Johnson; Eric C Strain; Roland R Griffiths
Journal:  Exp Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.157

3.  Cardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals.

Authors:  Sd Lane; Ce Green; Jl Steinberg; L Ma; Jm Schmitz; N Rathnayaka; Sd Bandak; S Ferre; Fg Moeller
Journal:  J Addict Res Ther       Date:  2012-03-28

4.  Human Pharmacology of Mephedrone in Comparison with MDMA.

Authors:  Esther Papaseit; Clara Pérez-Mañá; Julián-Andrés Mateus; Mitona Pujadas; Francina Fonseca; Marta Torrens; Eulàlia Olesti; Rafael de la Torre; Magí Farré
Journal:  Neuropsychopharmacology       Date:  2016-05-20       Impact factor: 7.853

5.  Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine.

Authors:  Scott D Lane; Charles E Green; Joy M Schmitz; Nuvan Rathnayaka; Wendy B Fang; Sergi Ferré; F Gerard Moeller
Journal:  J Addict Res Ther       Date:  2014

Review 6.  The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.

Authors:  Jack E Henningfield; Reginald V Fant; Daniel W Wang
Journal:  Psychopharmacology (Berl)       Date:  2017-12-23       Impact factor: 4.530

7.  Mephedrone and Alcohol Interactions in Humans.

Authors:  Esther Papaseit; Clara Pérez-Mañá; Elizabeth B de Sousa Fernandes Perna; Eulalia Olesti; Julian Mateus; Kim Pc Kuypers; Eef L Theunissen; Francina Fonseca; Marta Torrens; Jan G Ramaekers; Rafael de la Torre; Magí Farré
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.